CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Vasomotor, Sexual Symptoms Remain Problematic at 60-65 Years

Published: Mon, 19 Nov 2018 12:00:00 EST
Are HT guidelines meeting the needs of older postmenopausal women? This study indicates a high prevalence of untreated moderate to severe vasomotor and sexual symptoms even in women over age 60.
Menopause

Diagnosis of Lymphoid Lesions in Limited Samples

Published: Mon, 19 Nov 2018 12:00:00 EST
This review provides practical guidelines for diagnosis of lymphoid lesions in smaller samples obtained from minimally invasive procedures.
American Journal of Clinical Pathology

Effects of Dignity Therapy on Family Members

Published: Mon, 19 Nov 2018 12:00:00 EST
What is dignity therapy -- and what effects does it have on family members of patients with a serious illness?
Journal of Hospice and Palliative Nursing
Displaying results 10-12 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

Published: Thu, 15 Nov 2018 10:09:27 +0000
UniQure has posted eagerly anticipated data on the modified hemophilia B gene therapy it plans to take into phase 3. The FIX-Padua variant therapy achieved factor IX (FIX) activity levels of 23% to 37%, suggesting it is several times more effective than the version uniQure tested in earlier-phase trials.

Nektar nabs Genentech I-O leader Wei Lin to head up its oncology programs

Published: Wed, 14 Nov 2018 19:23:54 +0000
Nektar Therapeutics has poached Genentech cancer immunotherapy leader Wei Lin, M.D., to head up its oncology program and serve as VP of clinical development as it moves forward with its phase 3 trial with its lead combination therapy.

Eli Lilly files for FDA approval of migraine drug lasmiditan

Published: Wed, 14 Nov 2018 13:38:47 +0000
Eli Lilly has filed for FDA approval of migraine drug lasmiditan. The Big Pharma is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug clears headache pain in two hours in some patients.
Displaying results 10-12 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top